Skinvisible Adds Innovative Sunless Tanning Products Available for Exclusive Licensing
05 Noviembre 2013 - 1:31PM
Marketwired
Skinvisible Adds Innovative Sunless Tanning Products Available for
Exclusive Licensing
Invisicare(R) Suppresses Odor Associated With Sunless
Formulations
LAS VEGAS, NV--(Marketwired - Nov 5, 2013) - Skinvisible
Pharmaceuticals, Inc. (OTCQB: SKVI) is pleased to announce that is
has successfully developed new additions to its sunless tanning
product line formulated with its patented Invisicare® polymer
delivery technology. Skinvisible's sunless products address all of
the issues which are common with sunless tanning products,
specifically odor, streaking and the longevity of the tan. In
addition to the innovation in sunless tanning formulating,
Skinvisible has developed two new forms of application to add to
its pipeline of sunless tanning products including innovative
mousse and continuous spray formulations.
Skinvisible's sunless tanning products address the problems long
associated with sunless tanning products. A key problem with
applying sunless tanning is the unpleasant odor that is produced
during application and the "processing" time. The odor is due to
the chemical reaction between the dihydroxyacetone (DHA) and the
skin. Many products on the market use fragrances to try to mask the
odor which in many cases just exasperates the smell of the product.
Skinvisible products do not contain fragrances that try to cover-up
the smell; instead due to the chemical make-up of Invisicare, the
odor produced stays suppressed and neutralized within the
polymer.
"We have studies which have proven that when Invisicare is used
in sunless tanning products, it has the ability to suppress the
odor of the DHA and retain moisture in the skin, providing a much
longer lasting tan than products currently on the market," said
Terry Howlett, President and CEO. "This added benefit provides
consumers with a tan that lasts 50% to 70% longer." He added, "We
have also addressed ease of application with our Skinvisible's
formulations. Along with our lotions and professional spray
formulations, we have added a new mousse formulation and an
innovative continuous spray which allows you to spray from all
angles, even upside down and backwards. Unlike aerosols,
Skinvisible's continuous spray does not use harmful
propellants."
The sunless tanner / self tanning market is growing
exponentially. The market of US produced sunless tanning products
reached $609 million in 2012 and is forecasted to reach $940
million by 2016 according to IBIS World. The reason for the growth
is attributed to consumers' concern regarding the health risks such
as skin cancer and the government implementing stricter regulations
regarding tanning beds. These consumers are turning to self tanning
as a convenient alternative and are searching for longer-lasting
tans with convenient application methods without the odor.
Skinvisible's formulations have addressed all of these needs.
Skinvisible is seeking exclusive licensees for its high quality,
unique sunless tanning products. The product line consists of
light, medium and dark lotions, mousse and sprays along with
moisturizing "after-sun" products all with patent protection and
benefits that will resonate with consumers.
About Skinvisible
Pharmaceuticals, Inc Skinvisible Pharmaceuticals is a
research-and-development company that licenses its proprietary
formulations made with Invisicare, its patented polymer delivery
system that offers life-cycle management and unique enhancements
for topically delivered products. Invisicare holds active
ingredients on the skin for extended periods of time resisting both
wash off and perspiration along with controlling the release of
actives and reducing skin irritation. Skinvisible receives a
combination of license fees, and ongoing royalties for its licensed
product formulations. Skinvisible's value also lies in its ability
to continually generate new IP on topical products formulated with
Invisicare. www.skinvisible.com and www.invisicare.com .
Forward-Looking
Statements: This press release contains 'forward
looking' statements within the meaning of Section 21A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, and are subject to the
safe harbors created thereby. Such statements involve certain risks
and uncertainties associated with an emerging company. Actual
results could differ materially from those projected in the forward
looking statements as a result of risk factors discussed in
Skinvisible, Inc. reports on file with the U.S. Securities and
Exchange Commission (including, but not limited to, a report on
Form 10k for the quarter ending June 30, 2013).
Corporate Contact: Doreen McMorran Skinvisible Pharmaceuticals,
Inc. Phone: 702-433-7154 Email: info@skinvisible.com
Skinvisible (QB) (USOTC:SKVI)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Skinvisible (QB) (USOTC:SKVI)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024